NDC 0641-6003-01 - Ativan
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0641-6003
- Requested NDC
- 0641-6003-01
- Package NDCs from labels
- 0641-6003-01, 0641-6003-25
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Effective date
- 2026-09-16
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| ATIVAN Injection (lorazepam injection, USP) | Hikma Pharmaceuticals USA Inc. | 2026-09-16 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2012-07-24 | Indexing - Billing Unit |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0641-6003-01 | Ativan | 1 mL in 1 VIAL | INJECTION | 1 | 12 | |
| 0641-6003-25 | Ativan | 25 in 1 CARTON | INJECTION | 25 | 12 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0641-6003-01 | ML - Milliliter | 0641-6003 | 39234291-67c0-42e3-84e6-2343db75e106 | 1 | 2012-07-24 |
| 0641-6003-25 | ML - Milliliter | 0641-6003 | 36c00ab7-3d4c-4e2e-9097-56e1449101f1 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| LORAZEPAM | ACTIVE INGREDIENT | O26FZP769L | ATIVAN (LORAZEPAM) INJECTION ATIVAN (LORAZEAPM) INJECTION [WEST-WARD PHARMACEUTICAL CORP.] | 2 | |
| LORAZEPAM | ACTIVE MOIETY | O26FZP769L | ATIVAN (LORAZEPAM) INJECTION ATIVAN (LORAZEAPM) INJECTION [WEST-WARD PHARMACEUTICAL CORP.] | 2 | |
| BENZYL ALCOHOL | INACTIVE INGREDIENT | LKG8494WBH | ATIVAN (LORAZEPAM) INJECTION ATIVAN (LORAZEAPM) INJECTION [WEST-WARD PHARMACEUTICAL CORP.] | 2 | |
| POLYETHYLENE GLYCOL 400 | INACTIVE INGREDIENT | B697894SGQ | ATIVAN (LORAZEPAM) INJECTION ATIVAN (LORAZEAPM) INJECTION [WEST-WARD PHARMACEUTICAL CORP.] | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | ATIVAN (LORAZEPAM) INJECTION ATIVAN (LORAZEAPM) INJECTION [WEST-WARD PHARMACEUTICAL CORP.] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Walgreens Ultra Lubricant | POLYETHYLENE GLYCOL 400, AND PROPYLENE GLYCOL | Walgreens | 21dfe061-4533-2061-e063-6394a90a6e73 | 2025-10-17 | Warnings | 6DC9Q167V3 B697894SGQ |
| LOREEV XR | LORAZEPAM | Almatica Pharma LLC | 227734c1-bf01-9607-73ea-5a1f38a89bd9 | 2025-10-08 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | American Health Packaging | 45e31a87-a8db-4dda-b94b-83535b62e8e2 | 2025-09-14 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Dry eye relief | POLYETHYLENE GLYCOL AND PROPYLENE GLYCOL | CARDINAL HEALTH 110, LLC. DBA LEADER | f8da3af5-9172-4023-be82-0fd5bd891616 | 2025-09-12 | Warnings | 6DC9Q167V3 B697894SGQ |
| Systane COMPLETE | PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 2df0de02-a3e2-471a-9e10-040c3fba75fe | 2025-08-08 | Warnings | 6DC9Q167V3 |
| Systane Balance | PROPYLENE GLYCOL | Alcon Laboratories, Inc. | c7b1a03a-a5f2-409e-a34a-d6f166671de5 | 2025-08-07 | Warnings | 6DC9Q167V3 |
| Systane Ultra | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 0537c23a-15f7-be64-1231-a6c93468e9a8 | 2025-07-30 | Warnings | 6DC9Q167V3 B697894SGQ |
| Systane | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 1d679d0f-cec2-a644-79cd-079607254bb9 | 2025-07-30 | Warnings | 6DC9Q167V3 B697894SGQ |
| Systane Ultra Preservative Free | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 751fb85f-6683-4b0a-a650-324d4a74c5de | 2025-07-30 | Warnings | 6DC9Q167V3 B697894SGQ |
| Lorazepam | LORAZEPAM | Rising Pharma Holdings, Inc. | 386255e2-65aa-48ce-9eb1-246f1493cc14 | 2025-07-29 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Systane COMPLETE PF | PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 99b63d62-1cf0-4f28-8760-773917c2538a | 2025-07-29 | Warnings | 6DC9Q167V3 |
| Lorazepam | LORAZEPAM | Preferred Pharmaceuticals, Inc. | 00960fbd-a5da-408b-9867-62982f20906f | 2025-07-24 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | Preferred Pharmaceuticals, Inc. | 6cc1f35d-ff33-404e-aa5e-b01eab89863e | 2025-07-24 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Ativan | LORAZEPAM | Bausch Health US LLC | 89057c93-8155-4040-acec-64e877bd2b4c | 2025-07-09 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| LOREEV XR | LORAZEPAM | A-S Medication Solutions | c470fdee-8e18-4da9-b072-943d6b2518cf | 2025-07-03 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Visine Red Eye Hydrating Comfort Eye Drops | TETRAHYDROZOLINE HYDROCHLORIDE AND POLYETHYLENE GLYCOL 400 | Morning Star OTC | dcd4164c-aa1e-4f07-ab2c-b439275629db | 2025-06-16 | Warnings | B697894SGQ |
| Lorazepam | LORAZEPAM | Aphena Pharma Solutions - Tennessee, LLC | 3c20c89f-c8c3-43b3-837e-da413f449795 | 2025-05-27 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | Aphena Pharma Solutions - Tennessee, LLC | 17919c82-87f2-5030-e063-6294a90ac91a | 2025-04-21 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | Golden State Medical Supply, Inc. | 32fb5628-bf80-0135-e063-6294a90aa3ab | 2025-04-17 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | Aphena Pharma Solutions - Tennessee, LLC | 1791d5c9-9004-5c4b-e063-6294a90adf3d | 2025-04-08 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.